Suboptimal Responses in Chronic Myeloid Leukemia

Suboptimal Responses in Chronic Myeloid Leukemia

The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor progno...

Full description

Bibliographic Details
Main Authors: Jabbour, Elias, Saglio, Giuseppe, Hughes, Timothy P, Kantarjian, Hagop
Format: Online
Language:English
Published: Wiley Subscription Services, Inc., A Wiley Company 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412948/
id pubmed-3412948
recordtype oai_dc
spelling pubmed-34129482012-08-07 Suboptimal Responses in Chronic Myeloid Leukemia Jabbour, Elias Saglio, Giuseppe Hughes, Timothy P Kantarjian, Hagop Review Article The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor prognosis. In 2006, the European LeukemiaNet proposed criteria to identify patients with a suboptimal response to, or failure associated with, imatinib; these recommendations were updated in 2009. Suboptimal responders represent a unique treatment challenge. Although they may respond to continued imatinib therapy, their long-term outcomes may not be as favorable as those for optimally responding patients. Validation studies demonstrated that suboptimal responders are a heterogeneous group, and that the prognostic implications of suboptimal response vary by time point. There are few data derived from clinical trials to guide therapeutic decisions for these patients. Clinical trials are currently underway to assess the efficacy of newer tyrosine kinase inhibitors in this setting. Identification of suboptimal responders or patients failing treatment using hematologic, cytogenetic, and molecular techniques allows physicians to alter therapy earlier in the treatment course to improve long-term outcomes. Cancer 2012;. © 2011 American Cancer Society. Wiley Subscription Services, Inc., A Wiley Company 2012-03-01 2011-10-28 /pmc/articles/PMC3412948/ /pubmed/22038681 http://dx.doi.org/10.1002/cncr.26391 Text en Copyright © 2011 American Cancer Society http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Jabbour, Elias
Saglio, Giuseppe
Hughes, Timothy P
Kantarjian, Hagop
spellingShingle Jabbour, Elias
Saglio, Giuseppe
Hughes, Timothy P
Kantarjian, Hagop
Suboptimal Responses in Chronic Myeloid Leukemia
author_facet Jabbour, Elias
Saglio, Giuseppe
Hughes, Timothy P
Kantarjian, Hagop
author_sort Jabbour, Elias
title Suboptimal Responses in Chronic Myeloid Leukemia
title_short Suboptimal Responses in Chronic Myeloid Leukemia
title_full Suboptimal Responses in Chronic Myeloid Leukemia
title_fullStr Suboptimal Responses in Chronic Myeloid Leukemia
title_full_unstemmed Suboptimal Responses in Chronic Myeloid Leukemia
title_sort suboptimal responses in chronic myeloid leukemia
description The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor prognosis. In 2006, the European LeukemiaNet proposed criteria to identify patients with a suboptimal response to, or failure associated with, imatinib; these recommendations were updated in 2009. Suboptimal responders represent a unique treatment challenge. Although they may respond to continued imatinib therapy, their long-term outcomes may not be as favorable as those for optimally responding patients. Validation studies demonstrated that suboptimal responders are a heterogeneous group, and that the prognostic implications of suboptimal response vary by time point. There are few data derived from clinical trials to guide therapeutic decisions for these patients. Clinical trials are currently underway to assess the efficacy of newer tyrosine kinase inhibitors in this setting. Identification of suboptimal responders or patients failing treatment using hematologic, cytogenetic, and molecular techniques allows physicians to alter therapy earlier in the treatment course to improve long-term outcomes. Cancer 2012;. © 2011 American Cancer Society.
publisher Wiley Subscription Services, Inc., A Wiley Company
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412948/
_version_ 1611547919822880768

Similar Items